Inverness Gives Biosite Revised Commitment Letters From 'Proposed Financing Sources' | GenomeWeb
NEW YORK (GenomeWeb News) — Biosite said today that Inverness Medical Innovations has given the company a set of revised commitment letters from Inverness' “proposed financing sources” that will likely pay for its unsolicited bid to acquire Biosite for $90 a share. 
 
Biosite said it will file these revisions with the US Securities and Exchange Commission, but those changes are not yet available on the SEC’s website.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.